Financial Instruments and Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended									12 Months Ended																						12 Months Ended
	Sep. 27, 2013	Jun. 28, 2013		Mar. 29, 2013	Dec. 28, 2012	Sep. 28, 2012	Jun. 29, 2012	Mar. 30, 2012	Dec. 30, 2011	Sep. 27, 2013	Sep. 28, 2012	Sep. 30, 2011	Sep. 27, 2013 Spain and Italy	Sep. 28, 2012 Spain and Italy	Sep. 30, 2011 Spain and Italy	Sep. 27, 2013 CNS Therapeutics, Inc.	Oct. 01, 2012 CNS Therapeutics, Inc.	Sep. 27, 2013 Debentures 7.00% Debenture Level 2	Sep. 27, 2013 Debentures 8.00% Debenture Level 2	Sep. 27, 2013 Debentures 9.50% Debenture Level 2	Apr. 30, 2013 Senior Notes 3.50% Senior Note	Sep. 27, 2013 Senior Notes 3.50% Senior Note Level 1	Apr. 30, 2013 Senior Notes 4.75% Senior Note	Sep. 27, 2013 Senior Notes 4.75% Senior Note Level 1	Sep. 27, 2013 Carrying Value Level 1	Sep. 28, 2012 Carrying Value Level 1	Sep. 27, 2013 Carrying Value Level 3	Sep. 28, 2012 Carrying Value Level 3	Sep. 27, 2013 Recurring Level 1	Sep. 27, 2013 Recurring Level 2	Sep. 27, 2013 Recurring Level 3	Sep. 27, 2013 Recurring Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase (decrease) in rabbi trust securities																																$ 10,100,000
Fair value of contingent consideration upon acquisition																	6,900,000												0	0	6,900,000
Maximum contingent payments for acquisition																	9,000,000
Discount rate																1.00%
Restricted cash																									24,000,000	24,600,000
Cash surrender value of life insurance																											67,700,000	47,600,000
Increase (decrease) in cash surrender value of life insurance contracts										20,100,000
Stated interest rate																		7.00%	8.00%	9.50%	3.50%	3.50%	4.75%	4.75%
Net sales	$ 545,200,000	$ 570,000,000	[1]	$ 585,300,000	$ 504,000,000	$ 513,100,000	$ 516,300,000	$ 523,100,000	$ 503,700,000	$ 2,204,500,000	$ 2,056,200,000	$ 2,021,800,000	$ 51,700,000	$ 55,000,000	$ 60,200,000

[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.